Analysis by Optimly for Optimly AI Visibility, in the Optimly AI Brand Index. This Business Profile tracks the Brand Authority Index and supporting AI visibility evidence. Last analyzed August 17, 2026.
TYENNE (tocilizumab-aazg) is an FDA-approved biosimilar to Actemra® (tocilizumab) for the treatment of various inflammatory and autoimmune conditions, including moderately to severely active rheumatoid arthritis, giant cell arteritis, polyarticular and systemic juvenile idiopathic arthritis, CAR T cell-induced severe or life-threatening cytokine release syndrome, and hospitalized adult patients with COVID-19. It offers three administration options, including a pre-filled autoinjector pen.
AI did not recommend this brand in the limited public category test.
Optimly has not yet published a supported competitor set for Fresenius Kabi.
Brand Authority Index (BAI) tier: Emerging (exact score locked for unclaimed brands)
Official website: https://biosimilars.fresenius-kabi.com/
Last analyzed: August 17, 2026
This Business Profile is published by Optimly in the Optimly AI Brand Index, a public research dataset showing how AI systems describe brands, categories, and competitors. Optimly AI Visibility analyzes sampled buyer-intent responses, cited sources, and public brand information. The Brand Authority Index summarizes answer presence, narrative accuracy, and owned citations where sufficient evidence is available.
If this is your brand, you can claim this profile to verify its contents and correct what AI models say about you: Claim this profile